CN105592855A - 用于治疗肾衰竭的组合物和方法 - Google Patents

用于治疗肾衰竭的组合物和方法 Download PDF

Info

Publication number
CN105592855A
CN105592855A CN201480036565.3A CN201480036565A CN105592855A CN 105592855 A CN105592855 A CN 105592855A CN 201480036565 A CN201480036565 A CN 201480036565A CN 105592855 A CN105592855 A CN 105592855A
Authority
CN
China
Prior art keywords
angiotensin
patient
methods
hours
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480036565.3A
Other languages
English (en)
Chinese (zh)
Inventor
G·蒂德马什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Pharmaceutical Co filed Critical La Jolla Pharmaceutical Co
Publication of CN105592855A publication Critical patent/CN105592855A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201480036565.3A 2013-04-26 2014-04-25 用于治疗肾衰竭的组合物和方法 Pending CN105592855A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361816578P 2013-04-26 2013-04-26
US61/816,578 2013-04-26
PCT/US2014/035511 WO2014176534A1 (en) 2013-04-26 2014-04-25 Compositions and methods for treating renal failure

Publications (1)

Publication Number Publication Date
CN105592855A true CN105592855A (zh) 2016-05-18

Family

ID=51792411

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480036565.3A Pending CN105592855A (zh) 2013-04-26 2014-04-25 用于治疗肾衰竭的组合物和方法

Country Status (6)

Country Link
US (3) US9457059B2 (https=)
EP (2) EP2988770A4 (https=)
JP (4) JP6522584B2 (https=)
CN (1) CN105592855A (https=)
AU (4) AU2014256944B2 (https=)
WO (1) WO2014176534A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
EP2988770A4 (en) * 2013-04-26 2016-12-14 La Jolla Pharma Co COMPOSITIONS AND METHOD FOR TREATING KIDNEY FAILURES
PL2986308T3 (pl) 2013-12-18 2020-05-18 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Angiotensyna ii w połączeniu do leczenia niedociśnienia
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
PL3400000T3 (pl) 2016-01-07 2024-04-22 La Jolla Pharma, Llc Sposoby podawania angiotensyny ii
EP3235496A1 (en) * 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
US11202760B2 (en) 2016-09-30 2021-12-21 Xenamed Corp. Compositions of midodrine and methods of using the same
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
JP7364568B2 (ja) 2017-12-22 2023-10-18 ゼナメッド コーポレーション 持続放出ミドドリン塩酸塩組成物及び使用方法
MX2020013389A (es) 2018-06-15 2021-03-31 Ferring Bv Composiciones de terlipresina y usos de las mismas.
AU2019345313A1 (en) 2018-09-20 2021-03-18 Levo Therapeutics, Inc. Carbetocin drug product and process for preparing same
KR20210062638A (ko) 2018-09-20 2021-05-31 레보 테라퓨틱스 인코포레이티드 카르베토신의 안정한 비강내 제형
AU2020279395B2 (en) 2019-05-22 2025-08-28 Biovie Inc. Formulations of terlipressin
JP7694407B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694400B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694406B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694401B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694403B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694404B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694405B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1901941A (zh) * 2003-11-06 2007-01-24 通用电气医疗集团股份有限公司 血管紧张素ii与成像部分的缀合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
US6592865B2 (en) 2001-06-04 2003-07-15 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
WO2008059062A1 (en) * 2006-11-17 2008-05-22 Da Volterra Colonic delivery using zn/pectin beads with a eudragit coating.
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
KR20130026504A (ko) * 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
EP2988770A4 (en) * 2013-04-26 2016-12-14 La Jolla Pharma Co COMPOSITIONS AND METHOD FOR TREATING KIDNEY FAILURES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1901941A (zh) * 2003-11-06 2007-01-24 通用电气医疗集团股份有限公司 血管紧张素ii与成像部分的缀合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EDWARD T. SCHROEDER等: "Renal Failure in Patients with Cirrhosis of the Liver* III. Evaluation of Intrarenal Blood Flow by Para-aminohippurate Extraction and Response to Angiotensin", 《AMERICAN JOURNAL OF MEDICINE》 *
JOHN H. LARAGH等: "ANGIOTENSIN II, NOREPINEPHRINE, AND RENAL TRANSPORT OF ELECTROLYTES AND WATER IN NORMAL MAN AND IN CIRRHOSIS WITH ASCITES", 《JOURNAL OF CLINICAL INVESTIGATION》 *

Also Published As

Publication number Publication date
JP6962943B2 (ja) 2021-11-05
EP2988770A1 (en) 2016-03-02
AU2014256944A1 (en) 2015-11-26
AU2022201290B2 (en) 2024-06-13
JP6522584B2 (ja) 2019-05-29
US20220193183A1 (en) 2022-06-23
AU2019236749B2 (en) 2021-11-25
JP2022009125A (ja) 2022-01-14
EP3858437A1 (en) 2021-08-04
WO2014176534A1 (en) 2014-10-30
JP2019073529A (ja) 2019-05-16
EP2988770A4 (en) 2016-12-14
US20140329747A1 (en) 2014-11-06
JP2024009958A (ja) 2024-01-23
AU2019236749A1 (en) 2019-10-17
AU2022201290A1 (en) 2022-03-17
AU2014256944B2 (en) 2019-06-27
JP2016520573A (ja) 2016-07-14
US9457059B2 (en) 2016-10-04
CA2910601A1 (en) 2014-10-30
US20170014471A1 (en) 2017-01-19
AU2024219656A1 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
AU2022201290B2 (en) Compositions and methods for treating renal failure
US11219662B2 (en) Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II
TWI754225B (zh) 治療低血壓之方法
RS59804B1 (sr) Angiotenzin ii u kombinaciji za lečenje hipotenzije
JP2019508378A (ja) 昇圧薬の投与方法
US20200222493A1 (en) Methods for administering angiotensin ii
CA2910601C (en) Compositions and methods for treating renal failure
HK1224580A1 (en) Compositions and methods for treating renal failure

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1224580

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160518